AIM: To examine surgical specimens of pancreas with either chronic pancreatitis or pancreatic cancer in order to study whether ductal hyperplasia and dysplasia in pancreas represent precursor lesions for pancreatic cancer. METHODS: We examined expression of Ki-67, CEA, p53, and K-ras, in the surgical specimens of pancreas with adenocarcinomas (n=11) and chronic pancreatitis (n=12). Cellular proliferation was assessed by Ki-67 proliferation index using the proliferation marker Ki-67. In specimens with pancreas cancer, we divided pancreas epithelium into normal (n=7), ductal hyperplasia (n=3), dysplasia (n=4), and cancerous lesion (n=11) after hematoxylin and eosin staining, Ki-67, and CEA immunohistochemical staining. In cases with chronic pancreatitis, the specimen was pathologically examined as in cases with pancreas cancer, and they were also determined as normal (n=10), ductal hyperplasia (n=4), or dysplasia (n=5). p53 and K-ras expression were also studied by immunohistochemical staining. RESULTS: In pancreatic cancer, the Ki-67 index was 3.73+/-3.58 in normal site, 6.62+/-4.39 in ductal hyperplasia, 13.47+/-4.02 in dysplasia and 37.03+/-10.05 in cancer tissue, respectively. Overall, p53 was positive in normal ducts, ductal hyperplasia, dysplasia, and carcinoma cells in 0 of 14 (0%), 0 of 7 (0%), 7 of 9 (78%), and 10 of 11 (91%), respectively, and K-ras was positive in 0 of 8 (0%), 1 of 3 (33%), 4 of 6 (67%), 4 of 5 (80%), respectively. CONCLUSION: Our results favorably support the hypothesis that ductal hyperplasia and dysplasia of the pancreas might be precursor lesions for pancreas cancer. Further evaluation of oncogenes by the molecular study is needed.
AIM: To examine surgical specimens of pancreas with either chronic pancreatitis or pancreatic cancer in order to study whether ductal hyperplasia and dysplasia in pancreas represent precursor lesions for pancreatic cancer. METHODS: We examined expression of Ki-67, CEA, p53, and K-ras, in the surgical specimens of pancreas with adenocarcinomas (n=11) and chronic pancreatitis (n=12). Cellular proliferation was assessed by Ki-67 proliferation index using the proliferation marker Ki-67. In specimens with pancreas cancer, we divided pancreas epithelium into normal (n=7), ductal hyperplasia (n=3), dysplasia (n=4), and cancerous lesion (n=11) after hematoxylin and eosin staining, Ki-67, and CEA immunohistochemical staining. In cases with chronic pancreatitis, the specimen was pathologically examined as in cases with pancreas cancer, and they were also determined as normal (n=10), ductal hyperplasia (n=4), or dysplasia (n=5). p53 and K-ras expression were also studied by immunohistochemical staining. RESULTS: In pancreatic cancer, the Ki-67 index was 3.73+/-3.58 in normal site, 6.62+/-4.39 in ductal hyperplasia, 13.47+/-4.02 in dysplasia and 37.03+/-10.05 in cancer tissue, respectively. Overall, p53 was positive in normal ducts, ductal hyperplasia, dysplasia, and carcinoma cells in 0 of 14 (0%), 0 of 7 (0%), 7 of 9 (78%), and 10 of 11 (91%), respectively, and K-ras was positive in 0 of 8 (0%), 1 of 3 (33%), 4 of 6 (67%), 4 of 5 (80%), respectively. CONCLUSION: Our results favorably support the hypothesis that ductal hyperplasia and dysplasia of the pancreas might be precursor lesions for pancreas cancer. Further evaluation of oncogenes by the molecular study is needed.
Authors: A B Lowenfels; P Maisonneuve; G Cavallini; R W Ammann; P G Lankisch; J R Andersen; E P Dimagno; A Andrén-Sandberg; L Domellöf Journal: N Engl J Med Date: 1993-05-20 Impact factor: 91.245
Authors: Alexander W Jahng; Sonya Reicher; David Chung; Donna Varela; Rahul Chhablani; Anil Dev; Binh Pham; Jose Nieto; Rose J Venegas; Samuel W French; Bruce E Stabile; Viktor E Eysselein Journal: World J Gastrointest Endosc Date: 2010-11-16
Authors: Yuqing Zhang; Jingxuan Yang; Xiaobo Cui; Yong Chen; Vivian F Zhu; John P Hagan; Huamin Wang; Xianjun Yu; Sally E Hodges; Jing Fang; Paul J Chiao; Craig D Logsdon; William E Fisher; F Charles Brunicardi; Changyi Chen; Qizhi Yao; Martin E Fernandez-Zapico; Min Li Journal: EMBO Mol Med Date: 2013-07-16 Impact factor: 12.137
Authors: John Kokkinos; George Sharbeen; Koroush S Haghighi; Rosa Mistica C Ignacio; Chantal Kopecky; Estrella Gonzales-Aloy; Janet Youkhana; Paul Timpson; Brooke A Pereira; Shona Ritchie; Elvis Pandzic; Cyrille Boyer; Thomas P Davis; Lisa M Butler; David Goldstein; Joshua A McCarroll; Phoebe A Phillips Journal: Sci Rep Date: 2021-01-21 Impact factor: 4.379
Authors: Olivier Peulen; Arnaud Gonzalez; Paul Peixoto; Andrei Turtoi; Denis Mottet; Philippe Delvenne; Vincent Castronovo Journal: PLoS One Date: 2013-09-11 Impact factor: 3.240